This week in drug discovery (28 July – 1 August)
News round-up for 28 July – 1 August by DDW Senior Digital Content Editor Diana Turner.
With the Alzheimer’s Association International Conference (AAIC) taking place this week in Toronto, Canada, there have been a number of updates in the neuroscience drug discovery field.
The top stories:
Pegtarazimod reduces brain inflammation, says new study data
A new study has shown that pegtarazimod reduces microglial activation associated with pathogenic neuroinflammation in hypoxic ischaemic encephalopathy (HIE), as well as neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
First new ALS treatment approved in UK in 30 years
Biogen’s Qalsody (tofersen) has been approved in the UK as the first therapy to treat a rare, genetic form of amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND).
Roche’s AD study shows rapid clearance of amyloid plaques
Roche has shared new data from its Alzheimer’s development portfolio at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada.
Peptide for Alzheimer’s increases clearance of amyloid plaques
AltPep Corporation has presented new preclinical data on its lead compound, Soluble Oligomer Binding Inhibitor (SOBIN-AD), as a treatment for early Alzheimer’s disease (AD) at the Alzheimer’s Association International Conference (AAIC).
RWD shows shingles vaccine reduces dementia risk
GSK presented six abstracts at the Alzheimer’s Association International Conference (AAIC), including real-world data shows an association between recombinant zoster vaccine (RZV) and potential reduced risk of dementia.